Press Release : Roche announces the upcoming -2-

   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2019 employed about 98,000 people worldwide. In 
2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 
61.5 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit 
https://www.globenewswire.com/Tracker?data=33tu6f4Da0hunBBzDlnINlhG4-YsNAE1MAAnDFccCifn4P0j7VFxykKlfH7baRoqFEB9S-d_rlOk8ysITbkJJg== 
www.roche.com. 
 
 
 
   All trademarks used or mentioned in this release are protected by law. 
 
 
 
   *Production capacities are combined for both the SARS-CoV-2 Rapid 
Antigen Test (nasopharyngeal) and the new SARS-CoV-2 Rapid Antigen Test 
Nasal 
 
 
 
   References 
 
   [1] OASH Nasal Specimen Collection Fact Sheet - Updates 2020-11-11 
https://www.globenewswire.com/Tracker?data=glfQdGQPq3a6nGsHHjIZ6LDMf9-rSlW59aDwFVmA9fotp35gdTu5iiCpA46cW1vH9ymaKTDYFLr8l_RIjE3q-CUII68X7RxPF7Uzp-za2lLcWkdKEMcRDMzbZ263JRA1YZP4azyyt-cpcY19Iat1SM-H-0K9ZFV-OBjm4ITweC1yk2_HwR4_QL1ZHRQUxjfTmhNBbec_q1Zlgx9DBuOE4OOQHh0OnVVbIuIHRV9o60lWC6MpaMHSw-t_ByFTDGWB3_AK97ROQIJhkF9ACcX89Hp94rwAPYWTIMSIlU3YrJc= 
 
 
   [2] SD Biosensor. (2020). SARS-CoV-2 Rapid Antigen Test Nasal package 
insert 
 
   [3] European Centre for Disease Prevention and Control. Diagnostic 
testing and screening for SARS-CoV-2. 2020. 
 
   [4] Cerutti, Krüger, van Beek, Igloi, Krüttgen, Salvagno 
 
 
 
   Roche Group Media Relations 
 
   Phone: [phone] / e-mail: 
https://www.globenewswire.com/Tracker?data=3xcRqDVUc7CsNS9oAb1WfNM3QdxDbYMHKImS-MOEnIyelLV2FbpgczfHL3S3FmOEO6VN7kbps0WhwXkIjpLBwtljqsrhxP1CmXnXarsV7P2SQnCGTS-oZgnFTEF-DWRp 
[e-mail] 
 
 
 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein 
 Phone: [phone] 
 
 
 
 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: mailto:[e-mail] 
 [e-mail]                         [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: mailto:[e-mail] 
 [e-mail]                  [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]            e-mail: mailto:[e-mail] 
 [e-mail]                           [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
 
 
   Attachment 
 
 
   -- 01022021_MR_ Rapid Ag Nasal test_ EN 
      https://ml-eu.globenewswire.com/Resource/Download/b4f29e20-3519-4f4a-baff-b98919544be9

(END) Dow Jones Newswires

February 01, 2021 11:25 ET (16:25 GMT)